• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta.

作者信息

Witt P L, Storer B E, Bryan G T, Brown R R, Flashner M, Larocca A T, Colby C B, Borden E C

机构信息

Cancer Center, Medical College of Wisconsin, Milwaukee 53226-4801.

出版信息

J Immunother Emphasis Tumor Immunol. 1993 Apr;13(3):191-200. doi: 10.1097/00002371-199304000-00006.

DOI:10.1097/00002371-199304000-00006
PMID:8471593
Abstract

Interferons (IFNs) induce gene regulation in vivo that may be used to identify effective doses, schedules, and potential correlates of therapeutic response. To critically examine minimum effective dose, duration of response, and cumulative effects of repetitive doses, a range of subcutaneous doses of IFN beta ser was studied in 32 healthy human volunteers. IFN-induced products of gene regulation assessed were beta 2-microglobulin, neopterin, and tryptophan in serum and 2',5'-oligoadenylate (2-5A) synthetase activity in peripheral blood mononuclear cells. Eight subjects per group received 0.09, 0.9, 9, or 45 MU of IFN beta. Responses were measured at 24, 48, and 72 h after single and multiple doses. The lowest biologically effective dose was 0.9 MU; significant (p < 0.02) increases were observed at 24 h in beta 2-microglobulin and cellular 2-5A synthetase activity. At the two higher doses, 9 and 45 MU, changes were observed at 24 h in all products (p < 0.01). A dose response (p < 0.01) over the range of 0.09-45 MU was observed for all these serum and intracellular gene products. Changes in neopterin, beta 2-microglobulin, and cellular 2-5A synthetase correlated significantly with each other. The response to a single dose of IFN beta was as great in magnitude as the response to multiple doses, suggesting an alternate-day schedule would maintain biological response.

摘要

相似文献

1
Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta.
J Immunother Emphasis Tumor Immunol. 1993 Apr;13(3):191-200. doi: 10.1097/00002371-199304000-00006.
2
Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.在无可测血清浓度情况下干扰素对人体生物反应的调节作用:皮下注射与静脉注射β-丝氨酸干扰素的对比试验
J Natl Cancer Inst. 1989 Jul 19;81(14):1061-8. doi: 10.1093/jnci/81.14.1061.
3
Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.β干扰素和γ干扰素联合进行5天持续输注的生物学及临床效应
Cancer Res. 1990 Aug 1;50(15):4588-94.
4
Determination of 2'-5'-oligoadenylate synthetase in serum and peripheral blood mononuclear cells before and after subcutaneous application of recombinant interferon beta and gamma.
Eur J Clin Chem Clin Biochem. 1992 Sep;30(9):521-8. doi: 10.1515/cclm.1992.30.9.521.
5
A phase I study of recombinant interferon-beta in patients with advanced malignant disease.重组干扰素-β治疗晚期恶性疾病患者的I期研究。
Clin Cancer Res. 1999 Dec;5(12):3990-8.
6
A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.人用β-丝氨酸干扰素、γ-干扰素或β-丝氨酸干扰素与γ-干扰素联合使用对生物反应调节和临床副作用的直接比较。
J Clin Invest. 1990 Oct;86(4):1211-21. doi: 10.1172/JCI114827.
7
Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.重组人干扰素-β在健康男性志愿者体内的药代动力学和药效学
J Interferon Cytokine Res. 1996 Oct;16(10):759-64. doi: 10.1089/jir.1996.16.759.
8
A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.用于多发性硬化症的新型聚乙二醇化干扰素 β-1a:安全性、药理学和生物学。
J Clin Pharmacol. 2012 Jun;52(6):798-808. doi: 10.1177/0091270011407068. Epub 2011 Jun 16.
9
Absence of biological effects of orally administered interferon-beta ser.
J Interferon Res. 1992 Dec;12(6):411-3. doi: 10.1089/jir.1992.12.411.
10
Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.健康志愿者单次注射干扰素β-1a和干扰素β-1b的药效学比较。
J Interferon Cytokine Res. 1999 Nov;19(11):1257-64. doi: 10.1089/107999099312920.

引用本文的文献

1
Ingested (Oral) Adrenocorticotropic Hormone Inhibits IL-17 in the Central Nervous System in the Mouse Model of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.口服给予促肾上腺皮质激素抑制多发性硬化症和实验性自身免疫性脑脊髓炎小鼠模型中枢神经系统中的白介素-17。
Immunohorizons. 2022 Jul 22;6(7):497-506. doi: 10.4049/immunohorizons.2200023.
2
Ingested ACTH blocks Th17 production by inhibiting GALT IL-6.摄入的 ACTH 通过抑制 GALT IL-6 来阻断 Th17 的产生。
J Neurol Sci. 2020 Feb 15;409:116602. doi: 10.1016/j.jns.2019.116602. Epub 2019 Nov 27.
3
Interferons and their stimulated genes in the tumor microenvironment.
肿瘤微环境中的干扰素及其受刺激基因。
Semin Oncol. 2014 Apr;41(2):156-73. doi: 10.1053/j.seminoncol.2014.02.002. Epub 2014 Feb 14.
4
Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b.定点聚乙二醇化增强了干扰素β-1b 的药代动力学特性和抗肿瘤活性。
J Interferon Cytokine Res. 2013 Dec;33(12):769-77. doi: 10.1089/jir.2012.0148. Epub 2013 Aug 20.
5
Dose and Frequency of Administration of Interferon-beta Affect its Efficacy in Multiple Sclerosis.干扰素-β的剂量和给药频率影响其在多发性硬化症中的疗效。
Clin Drug Investig. 2003;23(9):551-9. doi: 10.2165/00044011-200323090-00001.
6
Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis.
Mol Diagn. 2004;8(3):185-94. doi: 10.1007/BF03260063.
7
Is multiple sclerosis a disease that requires frequent beta interferon dosing?多发性硬化症是一种需要频繁注射β干扰素的疾病吗?
J Neurol. 2004 Sep;251 Suppl 4:IV13-24. doi: 10.1007/s00415-004-1404-1.
8
Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.多发性硬化症患者中β干扰素的生物活性受治疗方案和中和抗体的影响。
J Neurol Neurosurg Psychiatry. 2004 Sep;75(9):1294-9. doi: 10.1136/jnnp.2004.037259.
9
Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.复发缓解型多发性硬化症免疫调节疗法的比较评估
CNS Drugs. 2002;16(8):563-78. doi: 10.2165/00023210-200216080-00005.
10
Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response.多发性硬化症中的β-干扰素疗法:临床相关剂量反应的证据
Drugs. 2001;61(12):1693-703. doi: 10.2165/00003495-200161120-00001.